Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bacterial Infections

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44366   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41050
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41051
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41052
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41053
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41054
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41055
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41056
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41057
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41058
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41059
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41060
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41061
    Study title:
    Active substance: Adsorbed Diphtheria toxoid, adsorbed Tetanus toxoid, adsorbed Pertussis antigens (Pertussis toxoid, Filamentous Haemagglutinin, Pertactin), adsorbed Inactivated poliovirus (type 1, type 2, type 3)
    Study summary document link (including results):
    View full study record
    Document reference: 41063
    Study title: "Simplified antitetanus vaccination Preliminary results of an African study"
    Active substance: Adsorbed tetanus vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41391
    Study title:
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47163
    Study title: Comparative Safety and lmmunogenicity Study of Diphtheria, Tetanus, Acellular Pertussis, Poliomyelitis Vaccine (DTacP-IPV) and Diphtheria, Tetanus, Whole-cell Pertussis, Poliomyelitis 1 1 Vaccine (TETRACOC!@) Given as a Second Booster to 4- to 7-year-old Children
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47159
    Study title: Comparative study of acellular and whole ce11 pertussis vaccines combined with diphtheria, tetanus and inactivated poliomyelitis type 1, 2, 3 vaccines in healthy infants (primary-immunisation and booster).
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47166
    Study title: Comparative study of the safety and immunogeniciîy of a DT Acellular Pertussis and a DT Whole cell Pertussis vaccine in Senegalese infants
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47165
    Study title: Randomised, Open Trial of the lmmunogenicity and Safety of Diphtheria, Tetanus, Acellular Pertussis (DTacP) Vaccine Associated or Combined with PRP-T Vaccine Given at 2-4-6 or 3-4-5 Months in Healthy Infants
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47160
    Study title: Safety and immunogenicity of a combined Diphtheria, Tetanus, acellular Pertussis. Haemophilus influenzae type b, enhanced inactivated trivalent Poliovirus vaccine administered as a single injection to healthy Chilean Infants
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47157
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Dec 31 10:11:45 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA